INTRODUCTION
============

In Taiwan, lung cancer is the leading cause of cancer death among women and the second leading cause among men.^[@r01]^ Cigarette smoking is considered to be the primary cause of lung cancer; however, less than 20% of smokers develop lung cancer.^[@r02],[@r03]^ Thus, it is possible that different individuals have different capacities for detoxification and DNA repair. Exposure to tobacco smoke might induce oxidative DNA damage that, when combined with impaired DNA repair, may increase lung cancer risk.^[@r04]--[@r07]^

Reactive oxygen species (ROS) are linked to chronic inflammation and lung cancer development.^[@r08],[@r09]^ Oxidative reactions due to ROS give rise to DNA modifications, which are then primarily repaired via a DNA base excision repair pathway. DNA repair is initiated by excision of damaged bases by specific DNA glycosylases, such as human 8-oxoguanine-DNA glycosylase (hOGG1) and apurinic/apyrimidinic endonuclease 1 (APE1).^[@r10]--[@r12]^ Research has shown that the product of the Ser326 allele of hOGG1 has an increased capacity for removing 8-hydroxyguanin and a high binding affinity for DNA.^[@r13],[@r14]^ In contrast, a biochemical assay showed that the product of the APE1 Asp148Glu allele had similar endonuclease and DNA binding activity to the wild-type allele.^[@r15]^

The association of the base excision repair genes hOGG1 and APE1 with lung cancer risk had been extensively investigated. Most of these studies were case-control studies that found an association between hOGG1 Ser326Cys polymorphism and increased lung cancer risk^[@r16]--[@r20]^; however, most found no association between APE1 Asp148Glu polymorphism and lung cancer risk.^[@r16],[@r21]--[@r23]^ The exception was 1 report that showed that APE1 Asp148Glu polymorphism was associated with lung cancer risk after adjusting for age, sex, and smoking.^[@r24]^ Interestingly, the hOGG1 and APE1 genetic polymorphisms were significantly associated with lung cancer risk in heavy smokers but not in light smokers or nonsmokers.^[@r16]--[@r22]^

p53 mutation, which is induced by carcinogens in cigarette smoke, frequently occurs in exons 5--8. This is the principal known carcinogenic pathway involved in lung cancer among smokers.^[@r25],[@r26]^ At this time, there is no molecular evidence to indicate any similar association of hOGG1 Ser326Cys or APE1Asp148Glu with lung cancer risk.

In the present study, we obtained tissue samples from lung tumors and adjacent normal lung from 217 Taiwanese patients with lung cancer. We examined p53 mutation in lung tumors by direct sequencing and used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to determine the existing genetic polymorphisms of hOGG1 and APE1 in the normal lung tissue. Genotyping analysis of both genes was confirmed in control subjects (*n* = 206) and accorded with the Hardy--Weinberg equilibrium ([eTable 1](#sm01){ref-type="supplementary-material"}). The aim of this study was to determine whether the hOGG1 Ser326Cys and APE1Asp148Glu genetic polymorphisms were associated with increased p53 mutation in lung cancer.

METHODS
=======

Participants
------------

From 1993 to 2005, surgical specimens were obtained from 217 patients at Taichung Veterans General Hospital, Taichung, Taiwan, ROC who had histologically or cytologically confirmed primary non--small cell lung cancer (NSCLC). All participants were older than 18 years and had incident primary lung cancer. Age ranged from 38 to 84 years. Written informed consent for the use of tumor specimens was obtained from each participant before surgery, as required by the Institutional Review Board at Taichung Veteran's General Hospital. Demographic data for each individual, including age, sex, tumor type and stage, and smoking status, were collected by interview and a review of hospital charts. Smokers were defined as current or previous smokers, and nonsmokers were defined as individuals who had never smoked.

Genotyping of the hOGG1 and APE1 polymorphisms
----------------------------------------------

Genotyping analysis of the hOGG1 Ser326Cys (C1245G) and APE1 Asp148Glu (T1350G) polymorphism from genomic DNA samples of adjacent normal lung tissue was conducted by PCR-RFLP as described previously.^[@r17],[@r21]^

Direct sequencing of the p53 gene
---------------------------------

To identify mutations in exons 5--8 of the p53 gene, an autosequencer (ABI 3100-Avant Genetic Analyzer; Applied Biosystems, Foster City, CA, USA) was used for direct sequencing of PCR products amplified from lung tumor tissues as described previously.^[@r27],[@r28]^

Statistical analysis
--------------------

Statistical analysis was performed using SPSS statistical software (Version 13.0 SPSS Inc., Chicago, IL, USA). Multiple logistic regression was also used to estimate odds ratio (ORs) and 95% CIs for the risk of increased mutation p53, as compared with the wild type, in lung cancer. A *P* value less than 0.05 was considered statistically significant.

RESULTS
=======

Association of hOGG1 Ser326Cys and APE1 Asp148Glu with p53 mutation in lung cancer
----------------------------------------------------------------------------------

PCR-RFLP analysis was used to examine the hOGG1 Ser326Cys and APE1 Asp148Glu polymorphisms. The association of the hOGG1 and APE1 polymorphisms with clinicopathologic parameters in Taiwanese with lung cancer is shown in Table [1](#tbl01){ref-type="table"}. No association with clinical parameters was seen for either gene polymorphism, except that men had a somewhat higher frequency than women of the APE1 Asp/Asp genotype (*P* = 0.049). Direct sequencing analysis showed that 97 of 217 (44.7%) lung tumor samples had p53 mutations. The frequencies of p53 mutation in men, smokers, and in squamous cell carcinomas were significantly higher than in women (*P* = 0.003), nonsmokers (*P* = 0.004), and adenocarcinomas (*P* = 0.001; Table [2](#tbl02){ref-type="table"}), respectively. In addition, the frequency of p53 mutation was higher in participants with late-stage tumors (II and III) than in those with early-stage tumors (I) (57% for stage II, 49% for stage III vs 34% for stage I).

###### Associations between clinical parameters and genotypes

  Characteristics       No.   hOGG1     *P*        APE1    *P*                 
  --------------------- ----- --------- ---------- ------- --------- --------- -------
  Age, y                                                                        
   \<66                 108   28 (26)   80 (74)    0.608   42 (39)   66 (61)   0.298
   ≥66                  109   25 (23)   84 (77)            50 (46)   59 (54)    
  Sex                                                                           
   Female               65    14 (22)   51 (78)    0.518   21 (32)   44 (68)   0.049
   Male                 152   39 (26)   113 (74)           71 (47)   81 (53)    
  Smoking status                                                                
   Nonsmoker            104   26 (25)   78 (75)    0.850   40 (38)   64 (62)   0.260
   Smoker               113   27 (24)   86 (76)            52 (46)   61 (54)    
  Tumor histology                                                               
   Adenocarcinoma       111   28 (25)   83 (75)    0.779   48 (43)   63 (57)   0.796
   Squamous carcinoma   106   25 (24)   81 (76)            44 (42)   62 (58)    
  Stage                                                                         
   I                    80    18 (23)   62 (77)    0.358   37 (46)   43 (54)   0.624
   II                   35    6 (17)    29 (83)            13 (37)   22 (63)    
   III                  102   29 (28)   73 (72)            42 (41)   60 (59)    

*P* values obtained from the chi-square test.

###### Association of p53 mutation with clinical characteristics of patients with lung cancer

  Characteristics            No.   p53 mutation   OR (95% CI)   *P*                 
  -------------------------- ----- -------------- ------------- ------------------- -------
  Age, y                                                                             
   \<66                      108   60 (56)        48 (44)       1                   0.940
   ≥66                       109   60 (55)        49 (45)       1.02 (0.59--1.74)    
  Sex                                                                                
   Female                    65    46 (71)        19 (29)       1                   0.003
   Male                      152   74 (49)        78 (51)       2.55 (1.37--4.15)    
  Smoking status                                                                     
   Nonsmoker                 104   68 (65)        36 (35)       1                   0.004
   Smoker                    113   52 (46)        61 (54)       2.22 (1.28--3.83)    
  Tumor histology                                                                    
   Adenocarcinoma            111   74 (67)        37 (33)       1                   0.001
   Squamous cell carcinoma   106   46 (43)        60 (57)       2.61 (1.50--4.53)    
  Stage                                                                              
   I                         80    53 (66)        27 (34)       1                    
   II                        35    15 (42)        20 (57)       2.62 (1.16--5.91)   0.021
   III                       102   52 (51)        50 (49)       1.89 (1.03--3.46)   0.039

We therefore examined whether p53 mutation was more frequent in participants with high-risk genotypes of hOGG1 and APE1 than in those with low-risk genotypes. p53 mutation in lung tumors of this study population was not associated with hOGG1 polymorphisms. However, participants with the APE1 Asp/Asp genotype had an OR of 2.15 (95% CI, 1.19--3.87; *P* = 0.011) for the risk of p53 mutation as compared with those with the APE1 Asp/Glu + Glu/Glu genotype after adjusting for covariates, including sex, smoking status, and tumor histology and stage (Table [3](#tbl03){ref-type="table"}).

###### Combined effects of hOGG1 and APE1 polymorphisms on p53 mutation in patients with lung cancer

  Genes                                   No.   p53 mutation   OR (95% CI)          *P* ^a^
  ------------------- ------------------- ----- -------------- -------------------- ---------
  hOGG1                                                                              
   Ser/Ser                                53    22             1                     
   Ser/Cys                                106   50             1.33 (0.66--2.69)    0.430
   Cys/Cys                                58    25             1.20 (0.81--4.36)    0.664
  Ser/Cys + Cys/Cys                       164   75             1.26 (0.65--2.45)    0.496
  APE1                                                                               
   Glu/Glu                                20    8              1                     
   Asp/Glu                                105   39             0.97 (0.35--2.72)    0.953
   Asp/Asp                                92    50             1.99 (0.69--5.76)    0.200
  Asp/Glu + Glu/Glu                       125   47             1                     
   Asp/Asp                                92    50             2.15 (1.19--3.87)    0.011
  hOGG1 and APE1                                                                     
   Ser/Ser            Asp/Glu + Glu/Glu   27    8              1                     
  Ser/Cys + Cys/Cys   Asp/Glu + Glu/Glu   98    39             2.08 (0.77--5.61)    0.148
   Ser/Ser            Asp/Asp             26    14             3.29 (0.94--11.51)   0.062
  Ser/Cys + Cys/Cys   Asp/Asp             66    36             3.72 (1.33--10.40)   0.012

^a^Adjusted for sex, smoking status, and tumor histology and stage.

We next examined the combined effects of hOGG1 and APE1 on p53 mutation in lung tumors after adjustment for covariates such as sex, smoking status, and tumor histology and stage. Participants with the Ser/Cys + Cys/Cys plus Asp/Asp had an OR of 3.72 (95% CI, 1.33--10.40; *P* = 0.012) for p53 mutation as compared with participants with the Ser/Ser plus Asp/Glu + Glu/Glu (Table [3](#tbl03){ref-type="table"}). The combined effects of polymorphisms in both genes on p53 mutation were not evident in other combinations, including Ser/Cys + Cys/Cys plus Asp/Glu + Glu/Glu and Ser/Ser plus Asp/Asp (Table [3](#tbl03){ref-type="table"}). Although differences in participants with the Ser/Ser plus Asp/Asp were not statistically significant, the OR for p53 mutation was 3.29 (95% CI, 0.94--11.51; *P* = 0.062; Table [3](#tbl03){ref-type="table"}). The lack of statistical significance could have been the result of the lower number of participants in this subgroup.

Effects of hOGG1 and APE1 polymorphisms on p53 mutation according to smoking status and tumor histology
-------------------------------------------------------------------------------------------------------

Participants were stratified by sex, smoking status, and tumor histology to determine whether hOGG1 and APE1 polymorphisms had differing effects on p53 mutation. The hOGG1 polymorphism was not associated with p53 mutation in the 6 subgroups (Table [4](#tbl04){ref-type="table"}). However, as shown in Table [5](#tbl05){ref-type="table"}, the APE1 polymorphism was associated with p53 mutation in nonsmokers (OR, 3.45; 95% CI, 1.39--8.53; *P* = 0.007) and in squamous cell carcinoma samples (3.21; 1.38--7.47, *P* = 0.007). The association of APE1 polymorphism with the risk of p53 mutation was marginal in both women and men (Table [5](#tbl05){ref-type="table"}). The OR for p53 mutation associated with APE1 polymorphism combined with hOGG1 polymorphism markedly increased, from 3.45 to 6.78 and from 3.21 to 8.11, in nonsmokers and squamous cell carcinoma, respectively (Table [6](#tbl06){ref-type="table"}). However, combined effects of hOGG1 and APE1 polymorphisms on the risk of p53 mutation were not seen in participants with adenocarcinoma (Table [6](#tbl06){ref-type="table"}).

###### Effect of hOGG1 polymorphism on p53 mutation in patients with lung cancer, according to sex, smoking status, and tumor histology

  Genes                     No.   p53 mutation   OR (95% CI)         *P*
  ------------------------- ----- -------------- ------------------- ----------
  Women                                                               
   Ser/Ser                  14    3              1                   0.655^a^
   Ser/Cys + Cys/Cys        51    16             1.39 (0.33--5.96)    
  Men                                                                 
   Ser/Ser                  39    19             1                   0.550^a^
   Ser/Cys + Cys/Cys        113   59             1.26 (0.59--2.70)    
  Nonsmokers                                                          
   Ser/Ser                  26    9              1                   0.954^b^
   Ser/Cys + Cys/Cys        78    27             1.03 (0.39--2.72)    
  Smokers                                                             
   Ser/Ser                  27    13             1                   0.364^b^
   Ser/Cys + Cys/Cys        86    48             1.52 (0.62--3.76)    
  Adenocarcinoma                                                      
   Ser/Ser                  28    11             1                   0.562^c^
   Ser/Cys + Cys/Cys        83    26             1.41 (0.44--4.50)    
  Squamous cell carcinoma                                             
   Ser/Ser                  25    11             1                   0.117^c^
   Ser/Cys + Cys/Cys        81    49             2.10 (0.38--5.30)    

^a^Adjusted for smoking status and tumor histology and stage.

^b^Adjusted for sex and tumor histology and stage.

^c^Adjusted for sex, smoking status, and tumor stage.

###### Effect of APE1 polymorphism on p53 mutation in patients with lung cancer, according to sex, smoking status, and tumor histology

  Gene                      No.   p53 mutation   OR (95% CI)          *P*
  ------------------------- ----- -------------- -------------------- ----------
  Women                                                                
   Asp/Glu + Glu/Glu        44    10             1                    0.056^a^
   Asp/Asp                  21    9              3.18 (0.97--10.43)    
  Men                                                                  
   Asp/Glu + Glu/Glu        81    37             1                    0.069^a^
   Asp/Asp                  71    41             1.88 (0.95--3.70)     
  Nonsmokers                                                           
   Asp/Glu + Glu/Glu        64    16             1                    0.007^b^
   Asp/Asp                  40    20             3.45 (1.39--8.53)     
  Smokers                                                              
   Asp/Glu + Glu/Glu        61    31             1                    0.348^b^
   Asp/Asp                  52    30             1.45 (0.67--3.18)     
  Adenocarcinoma                                                       
   Asp/Glu + Glu/Glu        63    19             1                    0.337^c^
   Asp/Asp                  48    18             1.52 (0.65--3.59)     
  Squamous cell carcinoma                                              
   Asp/Glu + Glu/Glu        62    28             1                    0.007^c^
   Asp/Asp                  44    32             3.21 (1.38--7.47)     

^a^Adjusted for smoking status and tumor histology and stage.

^b^Adjusted for sex and tumor histology and stage.

^c^Adjusted for sex, smoking status, and tumor stage.

###### Combined effects of hOGG1 and APE1 polymorphisms on p53 mutation in nonsmokers and participants with squamous cell carcinoma and adenocarcinoma

  Genes                                         No.   p53 mutation   OR (95% CI)          *P*
  ------------------------- ------------------- ----- -------------- -------------------- ----------
  Nonsmokers                                                                               
   Ser/Ser                  Asp/Glu + Glu/Glu   11    2              1                     
   Ser/Cys + Cys/Cys        Asp/Glu + Glu/Glu   53    14             1.66 (0.31--8.83)    0.553^a^
   Ser/Ser                  Asp/Asp             15    7              3.39 (0.48--23.57)   0.217^a^
   Ser/Cys + Cys/Cys        Asp/Asp             25    13             6.78 (1.03--44.56)   0.046^a^
  Squamous cell carcinoma                                                                 
   Ser/Ser                  Asp/Glu + Glu/Glu   15    4              1                     
   Ser/Cys + Cys/Cys        Asp/Glu + Glu/Glu   47    24             4.11 (1.01--16.82)   0.049^b^
   Ser/Ser                  Asp/Asp             10    7              7.08 (1.04--48.21)   0.045^b^
   Ser/Cys + Cys/Cys        Asp/Asp             34    25             8.11 (1.99--32.96)   0.003^b^
  Adenocarcinoma                                                                           
   Ser/Ser                  Asp/Glu + Glu/Glu   12    4              1                     
   Ser/Cys + Cys/Cys        Asp/Glu + Glu/Glu   51    15             0.98 (0.24--4.07)    0.980^c^
   Ser/Ser                  Asp/Asp             16    7              1.70 (0.30--9.57)    0.544^c^
   Ser/Cys + Cys/Cys        Asp/Asp             32    11             1.25 (0.26--5.45)    0.768^c^

^a^Adjusted for sex and tumor histology and stage.

^b^Adjusted for sex, smoking status, and tumor stage.

^c^Adjusted for sex, smoking status, and tumor stage.

DISCUSSION
==========

In this study, the prevalence of hOGG1 Cys/Cys was 26.7% (58 of 217) in Taiwanese with lung cancer. The distribution of hOGG1 Cys/Cys in this population was lower than in 2 previous studies of Taiwanese with lung cancer (39.8% and 36.9%). The prevalence of hOGG1 Cys/Cys in Japanese and Chinese adults with lung cancer ranged from 17.0% to 27.4% and from 16.9% to 36.1%, respectively. Interestingly, the prevalence of hOGG1 Cys/Cys in whites with lung cancer ranged from 2.7% to 18.2%, which is significantly lower than in Taiwanese, Japanese, and Chinese patient populations. The prevalence of the hOGG1 Cys/Cys genotype in this population was not higher than in other studies of Asian populations ([eTable 2](#sm01){ref-type="supplementary-material"}).

Substantial evidence indicates that hOGG1 Ser326Cys is associated with an increased risk of lung cancer.^[@r16]--[@r20]^ An early *in vitro* study provided cellular evidence that, as compared with the hOGG1 Ser/Ser genotype, the hOGG1-Cys variant results in less repair of 8-hydroxyguanine in damaged DNA.^[@r29]^ A more recent study confirmed this finding and also noted that the hOGG1-Cys variant resulted in less DNA glycosylase activity as compared with the hOGG1-Ser/Ser genotype. However, a biological function of hOGG1 Ser326Cys polymorphism was not supported, as the hOGG1-Cys variant was not associated with p53 mutation in patients with lung cancer.^[@r30]^ This discrepancy may have been due to the predominant influence of APE1 on the DNA glycosylase activity of hOGG1. In the present study, we consistently found that the hOGG1 Ser326Cys polymorphism was not associated with p53 mutation in the present population; however, p53 mutation was significantly more frequent in participants who had hOGG1-Cys alleles plus the APE1 Asp/Asp genotype. This finding lends support to the hypothesis that hOGG1 activity in the repair of oxidative damage to DNA is strongly regulated by APE1.

Findings regarding an association between the APE1 Asp148Glu polymorphism and lung cancer risk have been inconsistent. A recent study showed that lung cancer risk was higher for the APE1-Glu variant than for the APE1 Asp/Asp genotype,^[@r24]^ whereas other studies found no association between APE1 polymorphism and lung cancer risk.^[@r16],[@r21]--[@r23]^ Another report found that lung cancer was lower for the APE1-Glu variant than for the APE1 Asp/Asp genotype, especially in smokers.^[@r31]^ In addition, individuals with advanced NSCLC who had the APE1-Glu variant had poorer responses to chemotherapy and radiotherapy than did those with the APE1 Asp/Asp genotype.^[@r32]^ An *in vitro* biochemical study found that endonuclease activity and DNA binding activity were unaffected by APE1 Asp148Glu polymorphism.^[@r15]^

In the present study, APE1 polymorphism was associated with p53 mutation in patients with squamous cell carcinoma, which is more common among smokers. However, an association between APE1 polymorphism and p53 mutation was seen only in nonsmokers (Table [5](#tbl05){ref-type="table"}). Among nonsmokers, 8 of 10 Asp/Asp (80%) carriers versus 5 of 16 Asp/Glu + Glu/Glu (31%) carriers with p53 mutation had squamous cell carcinoma; however, 12 of 30 Asp/Asp carriers (40%) versus 11 of 48 Asp/Glu + Glu/Glu (23%) with p53 mutation had adenocarcinoma. Therefore, the association of APE1 polymorphism with p53 mutation in nonsmokers was higher among those with squamous cell carcinoma than in those with adenocarcinoma.

Combined APE1 and hOGG1 polymorphism markedly increased the risk of p53 mutation in nonsmokers and patients with squamous cell carcinoma (Table [6](#tbl06){ref-type="table"}). However, combined polymorphism did not increase the risk of p53 mutation in patients with adenocarcinoma (Table [6](#tbl06){ref-type="table"}). This could be due to the lower rate of p53 mutation in patients with adenocarcinoma as compared with squamous cell carcinoma patients (33% vs 57%, *P* = 0.001; Table [2](#tbl02){ref-type="table"}). These results suggest that the effects of hOGG1 and APE1 polymorphism on the risk of p53 mutation differ according to smoking status and tumor histology. However, these findings should be verified in a larger study population.

In summary, the risk of p53 mutation was higher among Taiwanese lung cancer patients with the APE1 Asp/Asp genotype than in those with the APE1-Glu variant. In addition, participants with the APE1 Asp/Asp genotype combined with hOGG1-Cys variant had the highest risk of p53 mutation.
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